At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metastatic triple-negative breast cancer (TNBC). In this interview, he gives us further insight to the results he shared and what these results could mean for the future of the TNBC treatment landscape.

Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan for TNBC

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: bit.ly/3HtOziO

Click here to listen to Module 1 of this series: bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: https://bit.ly/45u106o

Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: https://bit.ly/3HtOziO

Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Last Chance: Multiple Myeloma Task Force Podcast

Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025.

Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma.

Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

EXPIRING SOON! Mitigating Disease Burden and Healthcare Disparities in Multiple Myeloma

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind 

ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool. 

From Abstracts to Action: How ASCOmind Streamlines Oncology Insights With Xiaoyan Wang, PhD; William Oh, MD; and Waqas Haque, MD, MPH

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit: https://bit.ly/488fPhK

Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit:

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.

🎧 Listen now and click the link to claim your CE credit!

Claim your credit here: https://bit.ly/4pGrLO5

🔗 Learn more and access continuing education activities: https://i3health.com

📲 Stay connected with i3 Health:

Twitter/X: https://bit.ly/42VAYs1
LinkedIn: https://bit.ly/3IMiCmv
Facebook: https://bit.ly/46JrQI2
YouTube: https://bit.ly/4pNhWxR
Instagram: https://bit.ly/4nUSNzE
Threads: https://bit.ly/3Wd6oq9

🎧 Subscribe to the i3 Health Podcast on your favorite streaming platform so you never miss the latest expert discussions!

Optimizing CLL Care: Pharmacist-Led Strategies for Treatment Selection and Toxicity Management

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.

🎧 Listen now and click the link to claim your CE credit!

Claim your credit here: bit.ly/4pGrLO5

🔗 Learn more and access continuing education activities: i3health.com

📲 Stay connected with i3 Health:

Twitter/X: https://bit.ly/3ITDaJV
Facebook: https://bit.ly/46wmwJo
YouTube: https://bit.ly/46PXLXx

🎧 Subscribe to the Oncology Data Advisor Podcast on your favorite streaming platform so you never miss the latest expert discussions!

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan for TNBC

Oncology Data Advisor®

Related tracks